Samsung Biologics announced on November 2 that its public tender offer for Swiss peptide manufacturer PolyPeptide Group had reached an aggregate participation rate of 97.99%. The Korean pharmaceutical contract manufacturer is pursuing the acquisition through its Swiss subsidiary Samsung Peptide, seeking to add peptide drug manufacturing capabilities and an established international production network. The provisional result follows the close of the additional acceptance period on October 30.
According to the announcement, 32,350,302 PolyPeptide shares were validly tendered, representing 97.66% of the company's issued share capital and voting rights. Including shares held by the offeror and parties acting in concert, the aggregate participation reached 32,458,892 shares, or 97.99%. The definitive result is scheduled for publication on November 5.
Samsung Biologics first announced the all-cash acquisition in July at CHF 44.31 per share, valuing PolyPeptide's equity at approximately CHF 1.46 billion. The offer received the support of PolyPeptide's independent board members, while its largest shareholder had already committed to tender its holdings.
PolyPeptide operates six GMP-certified manufacturing facilities across Europe, the United States and India. Its business focuses on peptide-based active pharmaceutical ingredients, including development and commercial manufacturing services with exposure to GLP-1 therapies and other treatments for metabolic diseases.
The expected November 13 settlement has been postponed pending remaining regulatory approvals. Samsung Biologics now anticipates closing the acquisition towards the end of 2026 or in the first quarter of 2027. Following settlement, Samsung Peptide intends to acquire remaining minority shares and seek PolyPeptide's delisting from the SIX Swiss Exchange.
